reports
Novo Nordisk A/S - share repurchase programme
Novo Nordisk A/S - share repurchase programme Bagsværd, Denmark, 17 May 2024 – On 6 May 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 20 billion to be executed during a 12-month period beginning 6 February 2024. Under the programme initiated 6 May 2024, Novo Nordisk will repurchase B share...
- ABGSC Capital Goods Research
- Anders Idborg
- Karl Bokvist
- Olof Cederholm
VOLV B VOLVO AB CLASS B
WRT1V WARTSILA OYJ ABP
ABB ABB LTD.
SAND SANDVIK AB
TREL B TRELLEBORG AB CLASS B
MOCORP METSO OUTOTEC OYJ
ASSA B ASSA ABLOY AB CLASS B
SKF B SKF AB CLASS B
HPOL B HEXPOL AB CLASS B
ALFA ALFA LAVAL AB
MTRS B MUNTERS GROUP
HEXA B HEXAGON AB
EPI A EPIROC AB
NIBE B NIBE INDUSTRIER AB
ATCO A ATLAS COPCO AB
ALIV SDB AUTOLIV INC.
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, exe...
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons Bagsværd, Denmark, 15 May 2024 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse. The company’s board members, executives and their associated persons have reported the transactions to Novo Nordisk and have given Novo Nordisk power of attorney on their behalf to publish trading in Novo Nordisk shares...
GROUPE SEB : Descriptif du programme de rachat d’actions 2024-2025
ECULLY, France--(BUSINESS WIRE)-- Regulatory News: GROUPE SEB (Paris:SK): Etabli en application des dispositions des articles 241-1 et suivants du Règlement Général de l’Autorité des Marchés Financiers (AMF), le présent document a pour objet de décrire les objectifs et les modalités du programme de rachat d’actions qui sera soumis à l’autorisation de l’Assemblée générale mixte des actionnaires du 23 mai 2024, et dont la mise en œuvre commencera le 24 mai 2024. INTRODUCTION A la date du 30 avril 2024, le capital de la Société est composé de 55 337 770 actions (code ISIN de cotation: FR0...
- Stephane Beyazian
- Stephane Beyazian
- Damien Choplain
- Martial Descoutures
Novo Nordisk : Mim8 officially in competition with Hemlibra
>Positive results for the FRONTIER2 trial evaluating Mim8 in haemophilia A - Novo reported yesterday evening the clinical results of its phase 3 trial evaluating Mim8 in haemophilia A. Some 250 patients with haemophilia A and with or without inhibitors were included in the trial. The primary endpoint was to demonstrate control of bleeding episodes. Note that this trial was structured between 2 patient cohorts: one with no initial prophylaxis treatment treatment (n=57)...
- Damien Choplain
- Martial Descoutures
Novo Nordisk : Mim8 officiellement en concurrence avec Hemlibra
>Résultats positifs de l’essai FRONTIER2 évaluant Mim8 en hémophilie A - Novo publiait hier soir les résultats cliniques de son essai de phase 3 évaluant Mim8 en hémophilie A. 250 patients atteints d’hémophilie A présentant ou non des inhibiteurs étaient inclus dans cet essai. Le critère primaire est de démontrer un contrôle des saignements. Il faut noter que cet essai a été structuré entre 2 cohortes de patients : l’une ayant initialement aucune prophylaxie (n=57) et...
Novo Nordisk A/S: Once-weekly and once-monthly Mim8 demonstrate superi...
Novo Nordisk A/S: Once-weekly and once-monthly Mim8 demonstrate superior reduction of treated bleeding episodes compared to on-demand and prior prophylaxis treatment in people with haemophilia A in the Frontier 2 trial Bagsværd, Denmark, 13 May 2024 – Novo Nordisk today announced the headline results from the FRONTIER 2 trial, a pivotal phase 3a, 26-week open-label, randomised, controlled, multi-arm trial in 254 people. The trial investigated the efficacy and safety of once-weekly and once-monthly subcutaneous Mim8 versus no prophylaxis and versus prior coagulation factor prophylaxis treatm...
KPN reports on progress of € 200m share buyback
KPN reports on progress of € 200m share buyback KPN has rKPN reports on progress of € 200m share buybackepurchased 1,995,227 KPN ordinary shares in the period from 6 May to 10 May 2024. The shares were repurchased at an average price of € 3.39 per share for a total consideration of € 6.8m. These repurchases were made as part of the € 200m share buyback started on 1 February 2024, and are part of KPN's commitment to structurally return additional capital to its shareholders. The total number of ordinary shares repurchased to date is 54,001,838 for a total consideration of € 179.4m. Transac...
- Carole Braudeau
- Carole Braudeau
- Bruno Cavalier
- Louis Boujard
- CFA
- Philippe Ourpatian
MC LVMH MOET HENNESSY LOUIS VUITTON SE
UHR SWATCH GROUP LTD. BEARER
RMS HERMES INTERNATIONAL SCA
EL ESSILORLUXOTTICA SA
BRBY BURBERRY GROUP PLC
KER KERING SA
SDF K+S AG
G ASSICURAZIONI GENERALI S.P.A.
01913 PRADA S.P.A.
CRG CRH PLC
MONC MONCLER SPA
BC BRUNELLO CUCINELLI S.P.A.
CFR COMPAGNIE FINANCIERE RICHEMONT SA
- Bruno Cavalier
- Louis Boujard
- CFA
- Philippe Ourpatian
MC LVMH MOET HENNESSY LOUIS VUITTON SE
UHR SWATCH GROUP LTD. BEARER
RMS HERMES INTERNATIONAL SCA
EL ESSILORLUXOTTICA SA
BRBY BURBERRY GROUP PLC
KER KERING SA
SDF K+S AG
G ASSICURAZIONI GENERALI S.P.A.
01913 PRADA S.P.A.
CRG CRH PLC
MONC MONCLER SPA
BC BRUNELLO CUCINELLI S.P.A.
CFR COMPAGNIE FINANCIERE RICHEMONT SA
- Michael B. Schäfer
K+S AG : Final Q1 confirm strong prelim Q1-EBITDA on strong European s...
>Final Q1 EBITDA of € 200m confirm preliminary results vs. € 162m in Q4 23 - K+S already reported preliminary Q1 results on 30 April, beating consensus EBITDA expectations by 21% with €200m compared to €165m at consensus, also confirming €500-650m (cons € 562m) EBITDA outlook range back then. Final Q1 24 EBITDA gained 23% q/q to € 200m compared to € 162m in Q4 23, despite sequentially stable Ag volumes of 2mt and stable Ag ASP of € 336/t, i.e. positive mix at European...
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, exe...
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons Bagsværd, Denmark, 8 May 2024 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse. The company’s board members, executives and their associated persons have reported the transactions to Novo Nordisk and have given Novo Nordisk power of attorney on their behalf to publish trading in Novo Nordisk shares by...
Nombre d'actions et de droits de vote au 30 avril 2024
Nombre d'actions et de droits de vote au 30 avril 2024 7 mai 2024 Orange : Information relative au nombre total d’actions et de droits de vote prévue par l’article L. 233-8 II du Code de commerce et l’article 223-16 du Règlement général de l’Autorité des Marchés Financiers En application de l’article L. 22-10-46 du Code de commerce, il est automatiquement conféré, à compter du 3 avril 2016, un droit de vote double aux actions entièrement libérées inscrites au nominatif depuis deux ans au nom d’un même actionnaire. DateNombre d’actions composant le capitalNombre d’actions auto-détenues pri...
Total number of shares and voting rights at April 30, 2024
Total number of shares and voting rights at April 30, 2024 7 May 2024 Orange: information on the total number of shares and voting rights referred to in Article L.233-8 II of the French Commercial Code and Article 223-16 of the General Regulations of the Autorité des Marchés Financiers. In application of Article L. 22-10-46 of the French Commercial Code (Code de commerce), as from 3 April 2016, a double voting right is automatically granted to fully paid-up shares that have been held in registered form and under a single shareholder name for at least two years. DateNumber of shares Numbe...
GROUPE SEB : DECLARATION MENSUELLE DU NOMBRE D’ACTIONS ET DE DROITS DE...
ECULLY, France--(BUSINESS WIRE)-- Regulatory News: Société déclarante Dénomination sociale SEB S.A (Paris:SK) Adresse du siège social 112 Chemin du Moulin Carron, 69130 Ecully-France Marché réglementé Euronext Paris - Compartiment A ISIN FR0000121709 Nombre d’actions et de droits de vote: 31 Mars 2024 30 avril 2024 Actions composant le capital social (1) 55 337 770 55 337 770 Droits de vote théoriques (2) 81 236 563 81 214 286 Droits de vote exerçables 80 268...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.